IL310132B2 - Methods of treatment and prevention of alzheimer's disease - Google Patents

Methods of treatment and prevention of alzheimer's disease

Info

Publication number
IL310132B2
IL310132B2 IL310132A IL31013224A IL310132B2 IL 310132 B2 IL310132 B2 IL 310132B2 IL 310132 A IL310132 A IL 310132A IL 31013224 A IL31013224 A IL 31013224A IL 310132 B2 IL310132 B2 IL 310132B2
Authority
IL
Israel
Prior art keywords
months
subject
determined
composition
relative
Prior art date
Application number
IL310132A
Other languages
English (en)
Hebrew (he)
Other versions
IL310132B1 (en
IL310132A (en
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of IL310132A publication Critical patent/IL310132A/en
Publication of IL310132B1 publication Critical patent/IL310132B1/en
Publication of IL310132B2 publication Critical patent/IL310132B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL310132A 2018-07-24 2019-07-23 Methods of treatment and prevention of alzheimer's disease IL310132B2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862702659P 2018-07-24 2018-07-24
US201862749614P 2018-10-23 2018-10-23
US201962824162P 2019-03-26 2019-03-26
US201962846902P 2019-05-13 2019-05-13
US201962874684P 2019-07-16 2019-07-16
PCT/US2019/043067 WO2020023530A2 (en) 2018-07-24 2019-07-23 Methods of treatment and prevention of alzheimer's disease

Publications (3)

Publication Number Publication Date
IL310132A IL310132A (en) 2024-03-01
IL310132B1 IL310132B1 (en) 2025-11-01
IL310132B2 true IL310132B2 (en) 2026-03-01

Family

ID=67551415

Family Applications (3)

Application Number Title Priority Date Filing Date
IL310132A IL310132B2 (en) 2018-07-24 2019-07-23 Methods of treatment and prevention of alzheimer's disease
IL280315A IL280315B2 (en) 2018-07-24 2019-07-23 Methods for treating and preventing Alzheimer's disease
IL323583A IL323583A (en) 2018-07-24 2025-09-25 Methods for treating and preventing Alzheimer's disease

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL280315A IL280315B2 (en) 2018-07-24 2019-07-23 Methods for treating and preventing Alzheimer's disease
IL323583A IL323583A (en) 2018-07-24 2025-09-25 Methods for treating and preventing Alzheimer's disease

Country Status (11)

Country Link
US (1) US20210324056A1 (cg-RX-API-DMAC7.html)
EP (1) EP3826674A2 (cg-RX-API-DMAC7.html)
JP (3) JP7541505B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210039402A (cg-RX-API-DMAC7.html)
CN (2) CN118924896A (cg-RX-API-DMAC7.html)
AU (2) AU2019309938B2 (cg-RX-API-DMAC7.html)
CA (1) CA3107370A1 (cg-RX-API-DMAC7.html)
IL (3) IL310132B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021000778A (cg-RX-API-DMAC7.html)
PH (1) PH12021500006A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020023530A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
PT4121007T (pt) * 2020-03-20 2025-09-25 Eisai R&D Man Co Ltd Formulações de anticorpo de protofibrila de péptido anti-beta amiloide de concentração alta e métodos de uso das mesmas
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
AU2021310926A1 (en) 2020-07-23 2023-03-23 Othair Prothena Limited Anti-abeta antibodies
WO2022035758A1 (en) * 2020-08-12 2022-02-17 The Cleveland Clinic Foundation Bace1 inhibitor treatment for suppressing cytokine storm
TW202300517A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2023111618A1 (en) * 2021-12-17 2023-06-22 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
WO2023114586A1 (en) * 2021-12-17 2023-06-22 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
KR20240142535A (ko) * 2022-02-02 2024-09-30 에자이 알앤드디 매니지먼트 가부시키가이샤 P-tau181 수준을 사용한 치료 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
MY169492A (en) * 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
AU2016208353B2 (en) * 2007-10-17 2017-07-20 Janssen Alzheimer Immunotherapy Immunotherapy regimes dependent on ApoE status
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
BRPI0906962B8 (pt) 2008-01-18 2021-05-25 Eisai R&D Man Co Ltd composto de aminodiidrotiazina fundido
SI2448968T1 (sl) 2009-06-29 2021-07-30 Bioarctic Ab Protitelesa, selektivna za protofibrile/oligomere na N-koncu skrajšanega amiloida-beta
WO2011106732A1 (en) * 2010-02-25 2011-09-01 Wyeth Llc Pet monitoring of ab-directed immunotherapy
CN110655573B (zh) 2010-02-26 2023-07-18 生命北极神经科学公司 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用
EP2665716B1 (en) 2011-01-21 2017-03-08 Eisai R&D Management Co., Ltd. Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
CN106661103B (zh) 2014-07-10 2020-11-03 生命北极神经科学公司 改进的Aβ初原纤维结合抗体
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
EP3405489A1 (en) * 2016-01-20 2018-11-28 Genentech, Inc. High dose treatments for alzheimer's disease
WO2017194789A1 (en) * 2016-05-13 2017-11-16 Institut Pasteur Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology
TWI735600B (zh) * 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗-N3pGlu類澱粉β肽抗體及其用途
KR102630042B1 (ko) * 2016-10-27 2024-01-29 에자이 알앤드디 매니지먼트 가부시키가이샤 알츠하이머병의 치료를 위한 항-a베타 원시섬유 항체 및 베타-세크레타제 bace1 억제제를 포함하는 조성물

Also Published As

Publication number Publication date
MX2021000778A (es) 2021-03-31
PH12021500006A1 (en) 2021-09-13
US20210324056A1 (en) 2021-10-21
CA3107370A1 (en) 2020-01-30
IL310132B1 (en) 2025-11-01
AU2019309938A1 (en) 2021-03-11
BR112021001272A2 (pt) 2021-04-27
IL323583A (en) 2025-11-01
AU2019309938B2 (en) 2026-04-02
CN112805031A (zh) 2021-05-14
WO2020023530A2 (en) 2020-01-30
WO2020023530A3 (en) 2020-03-12
JP2024112859A (ja) 2024-08-21
JP2021532126A (ja) 2021-11-25
KR20210039402A (ko) 2021-04-09
IL280315B1 (en) 2024-02-01
TW202019471A (zh) 2020-06-01
IL280315B2 (en) 2024-06-01
EP3826674A2 (en) 2021-06-02
CN118924896A (zh) 2024-11-12
IL280315A (en) 2021-03-25
IL310132A (en) 2024-03-01
JP2026097906A (ja) 2026-06-16
JP7541505B2 (ja) 2024-08-28
JP7875901B2 (ja) 2026-06-18
AU2026204903A1 (en) 2026-07-09

Similar Documents

Publication Publication Date Title
IL277577A (en) Antibody-based methods for the detection and treatment of Alzheimer's disease
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
SG11202011296VA (en) Compositions and methods for the treatment of parkinson's disease
IL288894A (en) Methods for the assessment and treatment of Alzheimer's disease and their applications
IL280315A (en) Methods of treatment and prevention of alzheimer's disease
IL269083A (en) Methods for preventing and treating heart disease
IL272097A (en) Compounds for the prevention and treatment of medical disorders and their uses
EP3773500A4 (en) COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE
PT3458045T (pt) Ebselen para uso no tratamento da doença de ménière
ZA202000558B (en) Prevention and/or treatment of neurodegenerative disease
IL265911A (en) Epilimod preparations and methods of using them in the treatment of Alzheimer's disease
ZA202101489B (en) Compositions and methods for the treatment of parkinson's disease
EP3398614A4 (en) AGENTS FOR PREVENTION AND / OR TREATMENT OF MORBUS ALZHEIMER
EP3610879A4 (en) COMPOSITION OF TREATMENT AND / OR PREVENTION OF ALZHEIMER'S DISEASE
PL3137097T3 (pl) Leczenie i profilaktyka choroby Alzheimera (AD)
EP3552632A4 (en) MEDICINAL COMPOSITION FOR TREATING AND PREVENTING CHRONIC DISEASE
PL3137094T3 (pl) Leczenie i profilaktyka choroby alzheimera (ad)
ZA201906964B (en) Prevention and/or treatment of inflammatory skin disease
IL268131A (en) A pharmaceutical composition comprising an oxazine derivative and its use in the treatment or prevention of alzheimer's disease
EP3646872A4 (en) MEANS FOR PREVENTION AND / OR TREATMENT OF ALZHEIMER'S MORBUS
EP3634979A4 (en) COMPOSITIONS AND METHODS OF TREATING ALZHEIMER'S MORBUS
HUE037501T2 (hu) Alzheimer-kór (AD) kezelése és megelõzése
ZA202001588B (en) Method of treating alzheimer's disease
HK40052061A (en) Methods of treatment and prevention of alzheimer's disease
HK40074615A (en) Methods for evaluation and treatment of alzheimer's disease and applications thereof